康众医疗(688607) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥66,617,343.21, a decrease of 5.46% compared to the same period last year[1]. - Net profit attributable to shareholders for Q3 2024 was ¥5,268,368.31, an increase of 19.50% year-on-year[1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥2,477,809.28, up 147.62% year-on-year[2]. - The basic earnings per share for Q3 2024 was ¥0.06, reflecting a 25.76% increase compared to the same period last year[2]. - Total operating revenue for the first three quarters of 2024 reached ¥195,501,808.26, an increase of 7.8% compared to ¥181,405,325.04 in the same period of 2023[16]. - Net profit for the first three quarters of 2024 was ¥12,591,909.69, a significant increase from ¥3,391,715.57 in 2023, representing a growth of 270.5%[17]. - Basic earnings per share for the first three quarters of 2024 were ¥0.14, compared to ¥0.04 in the same period of 2023, reflecting a 250% increase[18]. - The company recorded a total comprehensive income of ¥9,291,941.91 for the first three quarters of 2024, compared to ¥3,790,733.07 in 2023, representing an increase of 145.5%[18]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥25,114,240.01, an increase of 135.43% compared to the same period last year[5]. - The net cash flow from operating activities for Q3 2024 was ¥25,114,240.01, an increase of 135.5% compared to ¥10,667,195.08 in Q3 2023[20]. - The total cash inflow from investment activities reached ¥1,830,617,049.82, up from ¥1,229,356,179.99 in the same period last year, representing a growth of 48.9%[20]. - The net cash flow from investment activities was ¥19,266,144.37, a significant recovery from a negative cash flow of ¥59,161,322.73 in Q3 2023[20]. - The cash outflow from financing activities totaled ¥24,719,640.22, compared to ¥5,684,943.44 in Q3 2023, indicating an increase of 335.5%[20]. - The net increase in cash and cash equivalents for Q3 2024 was ¥21,279,841.59, contrasting with a decrease of ¥50,400,475.90 in Q3 2023[21]. - The ending balance of cash and cash equivalents was ¥263,454,691.58, up from ¥147,853,156.24 at the end of Q3 2023, marking an increase of 78.2%[21]. - The cash paid for investment activities was ¥107,500,465.52, significantly higher than ¥8,000,000.00 in Q3 2023, indicating a growth of 1,243.8%[20]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥948,891,980.23, a slight increase of 0.17% from the end of the previous year[2]. - As of September 30, 2024, the company's total assets amounted to approximately CNY 948.89 million, a slight increase from CNY 947.30 million at the end of 2023[12]. - The company's total current assets decreased to CNY 623.23 million from CNY 798.83 million, representing a decline of approximately 22%[12]. - The company's total debt was ¥95,239,051.91, an increase from ¥89,236,086.75 in the previous year, reflecting a growth of 5.6%[16]. - The total current liabilities decreased slightly to CNY 78.42 million from CNY 82.13 million, a decline of approximately 4.2%[13]. - The total equity attributable to shareholders of the parent company was ¥853,703,212.52, slightly down from ¥858,123,119.13 in 2023, showing a decrease of 0.5%[16]. Research and Development - Research and development expenses totaled ¥9,552,192.95 in Q3 2024, a decrease of 17.06% year-on-year, representing 14.34% of operating revenue[2]. - Research and development expenses for the first three quarters of 2024 totaled ¥30,522,635.51, down from ¥34,762,082.95 in 2023, indicating a decrease of 12.8%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,012[6]. Other Information - The company has not disclosed any new product developments or technological advancements in the current report[11]. - There are no significant changes in the shareholding structure or any new strategic initiatives mentioned in the report[10]. - The company has not indicated any future guidance or market expansion plans in the current quarter[11]. - The company reported a significant increase in contract liabilities, rising to CNY 6.63 million from CNY 2.78 million, an increase of about 138%[13]. - The company reported a total payment to employees of ¥56,638,771.87, which is an increase from ¥52,530,585.39 in the previous year[20]. - Tax payments increased to ¥7,783,497.28 from ¥4,651,048.18, reflecting a rise of 67.5%[20]. - The company experienced a foreign exchange loss of ¥3,682,869.02, compared to a loss of ¥4,465,664.81 in Q3 2023[21]. - The financial expenses for the first three quarters of 2024 were ¥478,307.26, a significant increase from a financial income of -¥4,301,120.39 in 2023[16].